Department of Hepatopancreatobiliary (HPB) Surgery, Guadalajara University Hospital, Guadalajara, Spain.
HPB (Oxford). 2011 May;13(5):320-3. doi: 10.1111/j.1477-2574.2010.00287.x. Epub 2011 Mar 10.
Resection of colorectal cancer (CRC) liver metastases (LM) in pathological liver (PL) patients (with cirrhosis or hepatopathy) is extremely rare. The aim of this study was to perform a multicentre, retrospective analysis of epidemiology, surgical techniques and outcomes in patients with PL who underwent hepatic resection for CRC-LM.
A retrospective, multicentre questionnaire was distributed to 15 hepatopancreatobiliary surgical units.
Only six of 15 (40%) HPB units reported any experience in the surgical resection of CRC-LM in patients with PL. Of the 20 patients identified, 10 had underlying cirrhosis and 10 had chronic hepatopathy. Their median age was 66 years (range: 49-81 years). Thirteen patients were male. Liver dysfunction was known preoperatively in 18 patients. All patients had Child-Pugh class A disease. Six patients had synchronous disease. There were a total of 38 lesions among the 20 patients, distributed at a median of one lesion per patient (range: 1-4 lesions). The median size of the lesions was 3.0 cm (range: 1.5-9.0 cm). Preoperative median carcinoembryonic antigen (CEA) was 32.3 ng/ml (range: 1-184 ng/ml). The surgical procedures performed included: sub-segmentectomy (n= 12); left lateral sectionectomy (n= 6); segmentectomy (n= 4); radiofrequency ablation (n= 3), and exploratory laparotomy (n= 4). Morbidity occurred in four patients (Clavien grades I [n= 1], II [n= 2] and IVa [n= 1]). Mortality was nil. An R0 resection margin was achieved in 15 of 16 patients. Twelve patients did not receive chemotherapy. In resected patients, 10 presented with relapse. The median disease-free and overall survival periods were 12.2 and 22.3 months, respectively.
When feasible, liver resection is the best option for CRC-LM in PL patients.
结直肠癌(CRC)肝转移(LM)在有肝硬化或肝病史的病理肝(PL)患者中极为罕见。本研究的目的是对接受肝切除术治疗 CRC-LM 的 PL 患者进行多中心回顾性分析,以了解其流行病学、手术技术和结果。
对 15 个肝胆胰外科单位进行了回顾性多中心问卷调查。
只有 15 个 HPB 单位中的 6 个(40%)报告了在 PL 患者中进行 CRC-LM 肝切除的任何经验。在确定的 20 名患者中,10 名患有基础肝硬化,10 名患有慢性肝病。他们的中位年龄为 66 岁(范围:49-81 岁)。13 名男性。18 名患者术前已知肝功能障碍。所有患者均为 Child-Pugh 分级 A 级疾病。6 名患者患有同步疾病。20 名患者共有 38 个病灶,中位数为每位患者一个病灶(范围:1-4 个病灶)。病灶的中位大小为 3.0cm(范围:1.5-9.0cm)。术前中位癌胚抗原(CEA)为 32.3ng/ml(范围:1-184ng/ml)。进行的手术包括:亚段切除术(n=12);左外侧叶切除术(n=6);节段切除术(n=4);射频消融术(n=3)和剖腹探查术(n=4)。有 4 名患者发生并发症(Clavien 分级 I [n=1]、II [n=2]和 IVa [n=1])。无死亡病例。16 名患者中有 15 名获得了 R0 切除边界。12 名患者未接受化疗。在接受切除的患者中,10 名出现复发。无病生存期和总生存期的中位数分别为 12.2 个月和 22.3 个月。
在可行的情况下,肝切除术是 PL 患者 CRC-LM 的最佳选择。